...基缺失，改变了受体ATP结合囊（ATP-binding pocket, ABP）角度，增强了肿瘤细胞对酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）的敏感性[ 16, 17]，Shigematsu等[ 18]发现19外显子突变的发生率最高，占EGF...
基于2个网页-相关网页
目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。
Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
应用推荐